Acute Lymphoblastic Leukemia

Stratification of patients by minimal residual disease results may be useful

Published in Cancer Weekly, May 20th, 2003

Now that there are methods for determining minimal residual disease in acute lymphoblastic leukemia, these should be included in clinical studies to assess their value.

According to recent research published in the journal Monatsschrift Kinderheilkunde, "Adequate treatment of childhood acute lymphoblastic leukemia (ALL) is currently able to provide a cure rate of 80%. Clinical features (e.g. age, WBC, organ involvement) and biological characteristics (translocations, immunophenotype, in vitro chemosensitivity) are used for prognostic assessment but have only limited predictive value for individual risk estimation.

"The in vivo sensitivity of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (2003-05-20)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry